Evaluation of lenalidomide (Revlimid[R]) to treat subjects with Cutaneous lupus erythematosus (CLE).(CONNECTIVE TISSUE DISORDERS)(Report): An article from: Journal of Drugs in Dermatology Rating: List Price: $9.95 Sale Price: $9.95 Availability: Available for download now Evaluation of lenalidomide (Revlimid[R]) to treat subjects with Cutaneous lupus erythematosus (CLE).(CONNECTIVE TISSUE DISORDERS)(Report): An article from: Journal of Drugs in Dermatology – Product Description
This digital document is an article from Journal of Drugs in Dermatology, published by Journal of Drugs in Dermatology, Inc. on December 1, 2009. The length of the article is 329 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Evaluation of lenalidomide (Revlimid[R]) to treat subjects with Cutaneous lupus erythematosus (CLE).(CONNECTIVE TISSUE DISORDERS)(Report)Author: UnavailablePublication: Journal of Drugs in Dermatology (Magazine/Journal)Date: December 1, 2009Publisher: Journal of Drugs in Dermatology, Inc.Volume: 8 Issue: 12 Page: 1154(1)Article Type: ReportDistributed by Gale, a part of Cengage Learning
Evaluation of lenalidomide (Revlimid[R]) to treat subjects with Cutaneous lupus erythematosus (CLE).(CONNECTIVE TISSUE DISORDERS)(Report): An article from: Journal of Drugs in Dermatology – Details
No features available.